CEVA Inc. (NASDAQ:CEVA) announced that CEVA management will participate in the following upcoming conference in March: 27th Annual ROTH Conference in Dana Point, California on Tuesday, March 10th. On Friday shares of CEVA Inc. (NASDAQ:CEVA) closed at $19.93. Company’s sales growth for last 5 years was 5.70% and EPS growth for next 5 years is recorded as 29.70%.
ALUMINA Limited says an Alcoa Inc. (NYSE:AA) review of the US company’s global smelting and refining operations won’t include the Alcoa World Alumina and Chemicals smelter at Portland in Victoria. Alcoa Inc. (NYSE:AA) in last trading activity advanced 0.70% to close at $14.48. Company weekly performance is -2.10% while its quarterly performance stands at -15.72%. Alcoa Inc. (NYSE:AA) is -18.28% away from its 52 week high.
Magnum Hunter Resources Corp. (NYSE:MHR) announced that the Company has appointed Charlie Gibson as Vice President of Reservoir Engineering effective March 2, 2015. Mr. Gibson, age 56, will report to Gary C. Evans, Chairman & CEO of Magnum Hunter. On last trading day Magnum Hunter Resources Corp. (NYSE:MHR) moved down -4.91% to close at $2.52. Its volatility for the week is 7.03% while volatility for the month is 8.21%. MHR’s sales growth for past 5 years was 89.10% and its EPS growth for past 5 years was -40.40%. Magnum Hunter Resources Corp. (NYSE:MHR) monthly performance is 9.09%.
TheStreet upgraded shares of China BAK Battery Inc (NASDAQ:CBAK) from an e+ rating to a hold rating in a report issued on Monday. China BAK Battery, Inc. (NASDAQ:CBAK) has 31.33% insider ownership while its institutional ownership stands at 1.10%. In last trading activity company’s stock closed at $2.52.
On March 5, Pfizer Inc. (NYSE:PFE) announced that Prevenar 13 was approved in the EU for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older. The approval did not come as a surprise as the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion on the approval of Prevenar 13 for this indication. On Friday shares of Pfizer Inc. (NYSE:PFE) closed at $33.97. Company’s sales growth for last 5 years was 0.10% and EPS growth for next 5 years is recorded as 2.17%.